argenx SE (ARGX)

375,00 -0,08 (-0,02 %) À la clôture : 04:00PM EDT

argenx SE

Laarderhoogtweg 25
Amsterdam 1101EB
Netherlands
31 10 703 8441
https://www.argenx.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 1 148

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc.	CEO & Executive Director	1,29M	S.O.	1972
Mr. Karl Gubitz	Chief Financial Officer	843,26k	S.O.	1970
Ms. Karen Massey	Chief Operating Officer	1,42M	S.O.	1979
Mr. Filip Borgions	VP & Global Head of Technical Operations	S.O.	S.O.	S.O.
Mr. Peter Ulrichts	Chief Scientific Officer	S.O.	S.O.	1980
Ms. Beth DelGiacco	VP and Global Head of Corporate Communications & Investor Relations	S.O.	S.O.	S.O.
Ms. Malini Moorthy	General Counsel	S.O.	S.O.	1970
Mr. Arjen Lemmen M.Sc.	Vice President of Corporate Development & Strategy	S.O.	S.O.	1985
Mr. Marc Schorpion	Global Head of Human Resources	S.O.	S.O.	1959
Ms. Andria Wilk	Global Head of Quality	S.O.	S.O.	1974

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Gouvernance d’entreprise

L’ISS Governance QualityScore de argenx SE en date du 1 avril 2024 est 5. Les scores principaux sont Audit : 4; Société : 2; Droits des actionnaires : 3; Compensation : 10.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.